Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets

All-stock transaction brings Tempest a portfolio of next-generation CAR-T assets, including TPST-2003, a clinical-stage dual-targeting CD-19/BCMA CAR-T with strategic partner-funded BLA filing in China planned for 2027 Operational runway extended to mid-2027, supporting multiple potential